MiR-122 Targets SerpinB3 and Is Involved in Sorafenib Resistance in Hepatocellular Carcinoma

The only first-line treatment approved for advanced hepatocellular carcinoma (HCC) is sorafenib. Since many patients experience drug resistance, the discovery of more effective therapeutic strategies represents an unmet clinical need. MicroRNA (MiR)-122 is downregulated in most HCCs, while oncogenic...

Descripción completa

Detalles Bibliográficos
Autores principales: Turato, Cristian, Fornari, Francesca, Pollutri, Daniela, Fassan, Matteo, Quarta, Santina, Villano, Gianmarco, Ruvoletto, Mariagrazia, Bolondi, Luigi, Gramantieri, Laura, Pontisso, Patrizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406326/
https://www.ncbi.nlm.nih.gov/pubmed/30717317
http://dx.doi.org/10.3390/jcm8020171

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406326/
https://www.ncbi.nlm.nih.gov/pubmed/30717317
http://dx.doi.org/10.3390/jcm8020171

Ejemplares similares